ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function
after 48 weeks of daily treatment. Additional outcome measures include refined measures of
sleep, behavioral and psychological symptoms typically observed in AD, changes in daily
functioning of participants and changes in caregiver burden, as well as changes in quality of
life measures of both, patients and caregivers during treatment with ANAVEX2-73.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Anavex Life Sciences Corp.
Collaborators:
Anavex Australia Pty Ltd. Anavex Canada Ltd. Anavex Germany GmbH